Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKI discontinuation in chronic myeloid leukemia with sustained deep molecular response
NL-OMON39316Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Nov 2012
- Countries
- 1
01
Overview
Open-label, single-arm trial in chronic myelogenous leukemia (CML), sponsored by Vrije University Medical Center. Primary endpoints: Molecular relapse-free survival after stopping TKI and Duration of MMR or better after stopping TKI therapy. Started Nov 2012; status: recruiting.
02
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON39316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39316.